Over the past 12 months, 7 insiders at ACADIA PHARMACEUTICALS INC filed 22 open-market SEC Form 4 transactions on ACAD: 0 purchases worth $0 and 22 sales worth $3.1M. Insiders have been net sellers over this period. The most recent filing was on Jun 26, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 26, 26 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 11.4K | $26.08 | $298K |
| May 26, 26 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 5.4K | $21.18 | $114K |
| May 4, 26 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.3K | $21.79 | $29K |
| May 4, 26 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 3.5K | $21.79 | $76K |
| Apr 7, 26 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.0K | $22.20 | $23K |
| Apr 7, 26 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 2.7K | $22.20 | $60K |
| Mar 26, 26 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.1K | $21.73 | $24K |
| Mar 26, 26 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 3.2K | $21.72 | $69K |
| Mar 25, 26 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 833 | $21.47 | $18K |
| Mar 25, 26 | Adams Catherine OwenChief Executive Officer | SELL | 11.6K | $21.47 | $250K |
| Mar 25, 26 | Jennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC | SELL | 3.8K | $21.47 | $83K |
| Mar 25, 26 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 4.2K | $21.47 | $90K |
| Mar 25, 26 | Elizabeth H.z. ThompsonEVP, Head of Research & Dev | SELL | 3.4K | $21.47 | $74K |
| Feb 9, 26 | Jennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC | SELL | 7.0K | $23.38 | $162K |
| Nov 18, 25 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 4.1K | $23.69 | $97K |
| Nov 18, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 10.3K | $23.69 | $243K |
| Nov 10, 25 | James M DalyDirector | SELL | 30.0K | $22.37 | $671K |
| Sep 15, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 3.5K | $23.65 | $83K |
| Sep 2, 25 | Elizabeth A. GarofaloDirector | SELL | 1.6K | $25.98 | $42K |
| Aug 18, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 22.0K | $25.18 | $554K |
| Jun 4, 25 | Laura BregeDirector | SELL | 14.4K | $21.78 | $315K |
| May 16, 25 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 2.0K | $20.00 | $40K |
| May 16, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 2.0K | $25.00 | $50K |
| May 2, 25 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.3K | $14.60 | $19K |
| May 2, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 3.5K | $14.60 | $51K |
| Apr 8, 25 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.0K | $14.82 | $15K |
| Apr 8, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 2.7K | $14.82 | $40K |
| Mar 26, 25 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.1K | $17.05 | $19K |
| Mar 26, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 3.2K | $17.05 | $54K |
| Mar 5, 25 | Elizabeth A. GarofaloDirector | SELL | 4.9K | $18.23 | $90K |
| Feb 24, 25 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 475 | $19.96 | $9K |
| Feb 24, 25 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 773 | $19.96 | $15K |
| Nov 19, 24 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 4.1K | $16.81 | $68K |
| Nov 19, 24 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 10.3K | $16.81 | $172K |
| Nov 19, 24 | Brendan TeehanEVP, COO, HEAD OF COMMERCIAL | SELL | 10.3K | $16.81 | $174K |
| Aug 19, 24 | Stephen DavisCEO | SELL | 31.7K | $15.28 | $485K |
| Aug 19, 24 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 9.7K | $15.28 | $149K |
| Aug 19, 24 | Brendan TeehanEVP, COO, HEAD OF COMMERCIAL | SELL | 9.5K | $15.28 | $146K |
| Jun 10, 24 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 975 | $14.79 | $14K |
| May 2, 24 | Stephen DavisCEO | SELL | 11.4K | $16.94 | $194K |
| May 2, 24 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.3K | $16.94 | $22K |
| May 2, 24 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 3.5K | $16.94 | $59K |
| May 2, 24 | Brendan TeehanEVP, COO, HEAD OF COMMERCIAL | SELL | 3.5K | $16.94 | $59K |
| Apr 8, 24 | Stephen DavisCEO | SELL | 17.7K | $17.87 | $317K |
| Apr 8, 24 | James KiharaPRINCIPAL ACCOUNTING OFFICER | SELL | 1.0K | $17.87 | $18K |
| Apr 8, 24 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 2.7K | $17.87 | $49K |
| Apr 8, 24 | Brendan TeehanEVP, COO, HEAD OF COMMERCIAL | SELL | 2.6K | $17.87 | $46K |
| Mar 27, 24 | Stephen DavisCEO | SELL | 17.7K | $17.90 | $317K |
| Mar 27, 24 | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | SELL | 5.4K | $17.90 | $97K |
| Mar 27, 24 | Brendan TeehanEVP, COO, HEAD OF COMMERCIAL | SELL | 5.1K | $17.90 | $92K |
Over the past 12 months, insiders at ACADIA PHARMACEUTICALS INC filed 0 open-market purchases worth $0 and 22 sales worth $3.1M on ACAD, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 26, 26.
7 different insiders at ACADIA PHARMACEUTICALS INC filed open-market SEC Form 4 transactions on ACAD over the last 12 months.
InsiderTape plots every ACAD insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every ACADIA PHARMACEUTICALS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →